Reviewed,
UniProtKB/Swiss-Prot Q02563 (SV2A_RAT)
Last modified
February 9, 2010.
Version 74.
History...
Clusters with 100%,
90%,
50% identity |
Documents (1) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Synaptic vesicle glycoprotein 2A Short name=Synaptic vesicle protein 2A Short name=Synaptic vesicle protein 2 | ||||
| Gene names |
| ||||
| Organism | Rattus norvegicus (Rat) | ||||
| Taxonomic identifier | 10116 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Glires › Rodentia › Sciurognathi › Muroidea › Muridae › Murinae › Rattus |
Protein attributes
| Sequence length | 742 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles. Ref.10 Ref.11 Ref.12 Receptor for the botulinium neurotoxin type A/BOTA. Ref.10 Ref.11 Ref.12 |
| Subunit structure | Interacts with SYT1/synaptotagmin-1 in a calcium-dependent manner. Binds the adapter protein complex AP-2. Ref.11 Ref.5 Ref.7 Ref.8 |
| Subcellular location | Cytoplasmic vesicle › secretory vesicle › synaptic vesicle membrane; Multi-pass membrane protein. Note: Enriched in chromaffin granules, not present in adrenal microsomes. Associated with both insulin granules and synaptic-like microvesicles in insulin-secreting cells of the pancreas. Ref.10 Ref.2 Ref.6 |
| Tissue specificity | Widely expressed throughout the brain (at protein level). Expressed by neural and endocrine cells of brain and spinal cord. Ref.2 |
| Post-translational modification | Phosphorylation by CK1 of the N-terminal cytoplasmic domain regulates interaction with SYT1. N-glycosylated. Ref.1 |
| Miscellaneous | Identified as the brain binding-site for the antiepileptic drug levetiracetam/lev. |
| Sequence similarities | Belongs to the major facilitator superfamily. |
Ontologies
| Keywords | |
|---|---|
| Biological process | Neurotransmitter transport Transport |
| Cellular component | Cell junction Cytoplasmic vesicle Membrane Synapse |
| Domain | Transmembrane |
| Molecular function | Receptor |
| PTM | Glycoprotein Phosphoprotein |
| Technical term | Direct protein sequencing |
| Gene Ontology (GO) | |
| Biological process | neurotransmitter transport Ref.3 Traceable author statement. Source: RGD transmembrane transportInferred from electronic annotation. Source: InterPro |
| Cellular component | cell junction Inferred from electronic annotation. Source: UniProtKB-KW integral to membrane Ref.3Inferred from direct assay. Source: RGD synaptic vesicle membrane Ref.3Inferred from direct assay. Source: RGD |
| Molecular function | protein binding Ref.5 Inferred from physical interaction. Source: UniProtKB receptor activityInferred from electronic annotation. Source: UniProtKB-KW transporter activity Ref.3Traceable author statement. Source: RGD |
| Complete GO annotation... | |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||
Molecule processing | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 742 | 742 | Synaptic vesicle glycoprotein 2A | PRO_0000084882 | |||||
Regions | |||||||||
| Topological domain | 1 – 169 | 169 | Cytoplasmic Potential | ||||||
| Transmembrane | 170 – 190 | 21 | Potential | ||||||
| Topological domain | 191 – 205 | 15 | Extracellular Potential | ||||||
| Transmembrane | 206 – 226 | 21 | Potential | ||||||
| Topological domain | 227 – 233 | 7 | Cytoplasmic Potential | ||||||
| Transmembrane | 234 – 254 | 21 | Potential | ||||||
| Topological domain | 255 – 262 | 8 | Extracellular Potential | ||||||
| Transmembrane | 263 – 283 | 21 | Potential | ||||||
| Topological domain | 284 – 294 | 11 | Cytoplasmic Potential | ||||||
| Transmembrane | 295 – 315 | 21 | Potential | ||||||
| Topological domain | 316 – 334 | 19 | Extracellular Potential | ||||||
| Transmembrane | 335 – 355 | 21 | Potential | ||||||
| Topological domain | 356 – 447 | 92 | Cytoplasmic Potential | ||||||
| Transmembrane | 448 – 468 | 21 | Potential | ||||||
| Topological domain | 469 – 598 | 130 | Extracellular Potential | ||||||
| Transmembrane | 599 – 619 | 21 | Potential | ||||||
| Topological domain | 620 – 626 | 7 | Cytoplasmic Potential | ||||||
| Transmembrane | 627 – 647 | 21 | Potential | ||||||
| Topological domain | 648 – 651 | 4 | Extracellular Potential | ||||||
| Transmembrane | 652 – 672 | 21 | Potential | ||||||
| Topological domain | 673 – 685 | 13 | Cytoplasmic Potential | ||||||
| Transmembrane | 686 – 708 | 23 | Potential | ||||||
| Topological domain | 709 – 712 | 4 | Extracellular Potential | ||||||
| Transmembrane | 713 – 731 | 19 | Potential | ||||||
| Topological domain | 732 – 742 | 11 | Cytoplasmic Potential | ||||||
| Region | 1 – 57 | 57 | Interaction with SYT1 | ||||||
| Region | 543 – 580 | 38 | BOTA-binding By similarity | ||||||
Amino acid modifications | |||||||||
| Modified residue | 65 | 1 | Phosphotyrosine By similarity | ||||||
| Modified residue | 66 | 1 | Phosphotyrosine By similarity | ||||||
| Modified residue | 80 | 1 | Phosphoserine By similarity | ||||||
| Modified residue | 81 | 1 | Phosphoserine By similarity | ||||||
| Modified residue | 84 | 1 | Phosphothreonine By similarity | ||||||
| Modified residue | 127 | 1 | Phosphoserine By similarity | ||||||
| Modified residue | 480 | 1 | Phosphotyrosine By similarity | ||||||
| Glycosylation | 498 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 548 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 573 | 1 | N-linked (GlcNAc...) Potential | ||||||
Experimental info | |||||||||
| Sequence conflict | 340 | 1 | C → F in AAA42188. Ref.1 | ||||||
Sequences
| ||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "The synaptic vesicle protein SV2 is a novel type of transmembrane transporter." Feany M.B., Lee S., Edwards R.H., Buckley K.M. Cell 70:861-867(1992) [PubMed: 1355409] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC RNA], GLYCOSYLATION. |
| [2] | "Identification, characterization, and molecular cloning of a novel transporter-like protein localized to the central nervous system." Gingrich J.A., Andersen P.H., Tiberi M., el Mestikawy S., Jorgensen P.N., Fremeau R.T. Jr., Caron M.G. FEBS Lett. 312:115-122(1992) [PubMed: 1426240] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 177-194 AND 372-381, TISSUE SPECIFICITY, SUBCELLULAR LOCATION. |
| [3] | "SV2, a brain synaptic vesicle protein homologous to bacterial transporters." Bajjalieh S.M., Peterson K., Shingal R., Scheller R.H. Science 257:1271-1273(1992) [PubMed: 1519064] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 1-40. Tissue: Brain. |
| [4] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Tissue: Brain. |
| [5] | "Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin." Schivell A.E., Batchelor R.H., Bajjalieh S.M. J. Biol. Chem. 271:27770-27775(1996) [PubMed: 8910372] [Abstract] Cited for: INTERACTION WITH SYT1. |
| [6] | "SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family." Janz R., Suedhof T.C. Neuroscience 94:1279-1290(1999) [PubMed: 10625067] [Abstract] Cited for: SUBCELLULAR LOCATION. |
| [7] | "AP-2 recruitment to synaptotagmin stimulated by tyrosine-based endocytic motifs." Haucke V., De Camilli P. Science 285:1268-1271(1999) [PubMed: 10455054] [Abstract] Cited for: INTERACTION WITH AP-2. |
| [8] | "Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin." Pyle R.A., Schivell A.E., Hidaka H., Bajjalieh S.M. J. Biol. Chem. 275:17195-17200(2000) [PubMed: 10747945] [Abstract] Cited for: PHOSPHORYLATION BY CK1, INTERACTION WITH SYT1. |
| [9] | "The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam." Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. Proc. Natl. Acad. Sci. U.S.A. 101:9861-9866(2004) [PubMed: 15210974] [Abstract] Cited for: CHARACTERIZATION AS BINDING-SITE FOR ANTIEPILEPTIC DRUG LEVETIRACETAM. |
| [10] | "SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment." Iezzi M., Theander S., Janz R., Loze C., Wollheim C.B. J. Cell Sci. 118:5647-5660(2005) [PubMed: 16306227] [Abstract] Cited for: FUNCTION, SUBCELLULAR LOCATION. |
| [11] | "SV2A and SV2C contain a unique synaptotagmin-binding site." Schivell A.E., Mochida S., Kensel-Hammes P., Custer K.L., Bajjalieh S.M. Mol. Cell. Neurosci. 29:56-64(2005) [PubMed: 15866046] [Abstract] Cited for: FUNCTION, INTERACTION WITH SYT1. |
| [12] | "SV2 is the protein receptor for botulinum neurotoxin A." Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. Science 312:592-596(2006) [PubMed: 16543415] [Abstract] Cited for: FUNCTION AS A BOTA RECEPTOR. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |
|---|---|
| EMBL GenBank DDBJ | L01788 Genomic RNA. No translation available. L05435 mRNA. Translation: AAA42188.1. BC092132 mRNA. Translation: AAH92132.1. |
| IPI | IPI00208115. |
| PIR | A43344. |
| RefSeq | NP_476558.2. |
| UniGene | Rn.11264 |
3D structure databases | |
| SMR | Q02563. Positions 162-344, 600-704. |
| ModBase | Search... |
Protein-protein interaction databases | |
| IntAct | Q02563. 2 interactions. |
| STRING | Q02563. |
Protein family/group databases | |
| TCDB | 2.A.1.22.1. major facilitator superfamily (MFS). |
PTM databases | |
| PhosphoSite | Q02563. |
Proteomic databases | |
| PRIDE | Q02563. |
Genome annotation databases | |
| Ensembl | ENSRNOT00000028760; ENSRNOP00000028760; ENSRNOG00000021182; Rattus norvegicus. [Genome view] |
| GeneID | 117559. |
| KEGG | rno:117559. |
| NMPDR | fig|10116.3.peg.16631. |
| UCSC | NM_057210. rat. |
Organism-specific databases | |
| CTD | 117559. |
| RGD | 619715. Sv2a. |
Phylogenomic databases | |
| eggNOG | roNOG15218. |
| HOVERGEN | Q02563. |
| OrthoDB | EOG922D4H. |
Gene expression databases | |
| ArrayExpress | Q02563. |
| Genevestigator | Q02563. |
| GermOnline | ENSRNOG00000021182. Rattus norvegicus. |
Family and domain databases | |
| InterPro | IPR011701. MFS_1. IPR016196. MFS_general_subst_transpt. IPR005829. Sugar_transporter_CS. IPR005988. SV2. [Graphical view] |
| PANTHER | PTHR11600:SF32. SV2. 1 hit. |
| Pfam | PF07690. MFS_1. 1 hit. [Graphical view] |
| TIGRFAMs | TIGR01299. synapt_SV2. 1 hit. |
| PROSITE | PS50850. MFS. 1 hit. [Graphical view] |
| ProtoNet | Search... |
Other Resources | |
| NextBio | 620423. |
Entry information
| Entry name | SV2A_RAT | ||||||||
| Accession | Primary (citable) accession number: Q02563 Secondary accession number(s): Q58DZ8 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation project | HPI (Human Proteome Initiative) | ||||||||

Clusters with


